Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology

Mucosal Immunology

Volumn 7, Issue 3, 2014, Pages 549-557

  Shirey, K A ^a   Lai, W ^a   Pletneva, L M ^b   Karp, C L ^c   Divanovic, S ^c   Blanco, J C G ^b   Vogel, S N ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Sigmovir Biosystems Inc   (United States)

^c CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CYCLOOXYGENASE 2; INDOMETACIN; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; LEUKOTRIENE B4; LEUKOTRIENE D4; LIPOXIN A; LIPOXYGENASE; MANNOSE RECEPTOR; MESSENGER RNA; ZILEUTON; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRONCHIOLITIS; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; HISTOPATHOLOGY; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; LUNG DISEASE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; PATHOLOGY; RAT; SIGNAL TRANSDUCTION; VIROLOGY;

ANIMALS; ARACHIDONATE 15-LIPOXYGENASE; ARACHIDONATE 5-LIPOXYGENASE; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, KNOCKOUT; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84891899101     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2013.71     Document Type: Article

References (36)

1. Welliver, R.C. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J. Pediatr 143, S112-S117 (2003).
2. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531-537 (1998).
3. Blanco, J.C.G., Boukhvalova, M.S., Shirey, K, Prince, G.A. & Vogel, S.N. New insights for development of a safe and protective RSV vaccine. Hum. Vaccine 6, 1-11 (2010).
4. Richardson, J.Y. et al. Respiratory syncytial virus (RSV) infection induces cyclooxygenase 2: a potential target for RSV therapy. J. Immunol 174, 4356-4364 (2005).
5. Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 3, 23-35 (2003).
6. Mosser, D.M. & Edwards, J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958-969 (2008).
7. Shirey, K. et al. Control of RSV-induced lung injury by alternatively activated macrophages is IL-4Ra-. TLR4-, and IFN-b-dependent. Mucosal Immunol 3, 291-300 (2010).
8. Serhan, C.N. & Haeggstrom, J.Z. Lipid mediators in acute inflammation and resolution: eicosanoids, PAF, resolvins, and protectins. In Fundamentals of Inflammation (Serhan, C.N. & Ward, P.A. & Gilroy, D.W., eds) pp 153-174 (Cambridge University Press, New York, NY, 2010).
9. Smith, W.L. Prostanoid biosynthesis and mechanisms of action. Am. J. Physiol. 263, F18 (1992).
10. Dubois, R.N. et al. Cyclooxygenase in biology and disease. FASEB J 12, 1063 (1998).
11. Karp, C.L. & Cooper, A.M. An oily, sustained counter-regulatory response to TB. J. Clin. Invest. 115, 1473-1476 (2005).
12. Wenzel, S.E. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy 17, 3S-12S (1997).
13. Rask-Madsen, J, Bukhave, K, Laursen, L.S. & Lauritsen, K. 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents Action Spec 36, C37-C46 (1992).
14. Blaho, V.A., Zhang, Y, Hugh-Hanks, J.M. & Brown, C.R. 5-Lipoxygenasedeficient mice infected with Borrelia burgdorferi develop persistent arthritis. J. Immunol. 186, 3076-3084 (2011).
15. Kuhn, H & O'Donnell, V.B. Inflammation and immune regulation by 12/15-lipoxygenases. Prog. Lipid Res 45, 334-356 (2006).
16. Prince, G.A., Prieels, J.P., Slaoui, M & Porter, D.D. Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccineenhanced disease in the cotton rat (Sigmodon hispidus). Lab. Invest. 79, 1385-1392 (1999).
17. Ohira, T. et al. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J. Biol. Chem 285, 3451-3461 (2010).
18. Behera, A.K., Kumar, M, Matsuse, H, Lockey, R.F. & Mohapatra, S.S. Respiratory syncytial virus induces the expression of 5-lipoxygenase and endothelin-1 in bronchial epithelial cells. Biochem. Biophys. Res.Commun 251, 704-709 (1998).
19. Weede-Beer, K, Hu, C, Rodriguez, M.M. & Piedimonte, G. Leukotrienes mediate inflammation in lungs of young rats infected with respiratory syncytial virus. Am. J. Physiol. Lung Cell Mol. Physiol 282, L1143-L1150 (1988).
20. Shay, D.K. et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282, 1440-1446 (1999).
21. Shay, D.K., Holman, R.C., Roosevelt, G.E., Clarke, M.J. & Anderson, L.J. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J. Infect. Dis. 183, 16-22 (2001).
22. Sigurs, N, Bjarnason, R, Sigurbergsson, F, Kjellman, B & Bjorksten, B. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 95, 500-505 (1995).
23. Graham, B.S. et al. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol 151, 2032-2040 (1993).
24. Radi, Z.A., Meyerholz, D.K. & Ackermann, M.R. Pulmonary cyclooxygenase-1 (COX-1) and COX-2 cellular expression and distribution after respiratory syncytial virus and parainfluenza virus infection. Viral Immunol 23, 43-48 (2010).
25. Carey, M.A. et al. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J. Immunol 175, 6878-6884 (2005).
26. Chen, W.H. et al. Potential role for alternatively activated macrophages in the secondary bacterial infection during recovery from influenza. Immunol. Lett 141, 227-234 (2012).
27. von Moltke, J. et al. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature 490, 107-111 (2012).
28. Tam, V.C. et al. Lipidomic profiling of influenza infection identifies mediators that induce and resolve inflammation. Cell 154, 213-227 (2013).
29. Dulek, D.E. & Peebles, R.S. Jr Viruses and asthma. Biochim. Biophys. Acta 1810, 1080-1090 (2011).
30. Du, L. et al. Binding investigation of human 5-lipoxygenase with its inhibitors by SPR technology correlating with molecular docking simulation. J. Biochem 139, 715-723 (2006).
31. Sordillo, L.M. et al. Enhanced 15-HPETE production during oxidant stress induces apoptosis on endothelial cells. Prostaglandins Other Lipid Mediat 76, 19-34 (2005).
32. Yokomizo, T, Kato,K,Hagiya, H, Izumi, T & Shimizu, T.Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J. Biol. Chem. 276, 12454-12459 (2001).
33. Carter, G.W. et al. 5-lipoxygenase inhibitory activity of zileuton. J. Pharmacol. Exp. Ther 256, 929-937 (1991).
34. Shirey, K, Cole, L.E., Keegan, A.D. & Vogel, S.N. Francisella tularensis LVS induces macrophage alternative activation as a survival mechanism. J. Immunol. 181, 4159-4167 (2008).
35. Waslidge, N.B. & Hayes, D.J. A colorimetric method for the determination of lipoxygenase activity suitable for use in a high throughput assay format. Anal. Biochem 231, 354-358 (1995).
36. Cho, Y.S., Kim, H.S., Kim, C.H. & Cheon, H.G. Application of the ferrous oxidation-xylenol orange assay for screening of 5-lipoxygenaes inhibitors. Anal. Biochem. 351, 62-68 (2006).